Emerging pharmacotherapies for COPD

Chest

Volumn 134, Issue 6, 2008, Pages 1278-1286

  Barnes, Peter J ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

Antiinflammatory; Bronchodilator; Chemokine; Cytokine; Histone deacetylase; Nuclear factor B; p38 mitogen activated protein kinase; Phosphodiesterase 4; Phosphoinositide 3 kinase

Indexed keywords

ACLIDINIUM BROMIDE; ADZ8309; ANTIINFLAMMATORY AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CARMOTEROL; CHEMOKINE RECEPTOR ANTAGONIST; CHEMOKINE RECEPTOR CXCR2; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; DOPAMINE 3 RECEPTOR BLOCKING AGENT; GLYCOPYRRONIUM BROMIDE; HISTONE DEACETYLASE 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDACATEROL; INFLIXIMAB; LIPOXYGENASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE P38; MUSCARINIC RECEPTOR BLOCKING AGENT; NICOTINE VACCINE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHODIESTERASE IV; PHOSPHOINOSITIDE 3 KINASE GAMMA; RIMONABANT; THEOPHYLLINE; TIOTROPIUM BROMIDE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VARENICLINE; VASODILATOR AGENT;

CHRONIC OBSTRUCTIVE LUNG DISEASE; CIGARETTE SMOKING; DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; DRUG SCREENING; DRUG TOLERANCE; ENZYME ACTIVITY; HUMAN; MONOCYTE; NEUTROPHIL; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SMOKING CESSATION; TOBACCO DEPENDENCE;

EID: 57349099228     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.08-1385     Document Type: Article

References (68)

1. Barnes PJ. Chronic obstructive pulmonary disease: a growing but neglected epidemic. PLoS Med 2007; 4:e112
2. Mannino DM, Buist AS. Global burden of COPD: risk factors, prevalence, and future trends. Lancet 2007; 370:765-773
3. Barnes PJ, Shapiro SD, Pauwels RA. Chronic obstructive pulmonary disease: molecular and cellular mechanisms. Eur Respir J 2003; 22:672-688
4. Barnes PJ, Stockley RA. COPD: current therapeutic interventions and future approaches. Eur Respir J 2005; 25:1084-1106
5. Barnes PJ. Frontrunners in novel pharmacotherapy of COPD. Curr Opin Pharmacol 2008; 8:300-307
6. Barnes PJ. Theophylline for COPD. Thorax 2006; 61:742-743
7. Barnes PJ. Immunology of asthma and chronic obstructive pulmonary disease. Nat Immunol Rev 2008; 8:183-192
8. Makita H, Nasuhara Y, Nagai K, et al. Characterisation of phenotypes based on severity of emphysema in chronic obstructive pulmonary disease. Thorax 2007; 62:932-937
9. Sturton G, Persson C, Barnes PJ. Small airways: an important but neglected target in the treatment of obstructive airway diseases. Trends Pharmacol Sci 2008; 29:340-349
10. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356:775-789
11. Barnes PJ, Chowdhury B, Kharitonov SA, et al. Pulmonary biomarkers in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006; 174:6-14
12. Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of COPD: 2006 update. Am J Respir Crit Care Med 2007; 176:532-555
13. 2-adrenoceptor agonists: an emerging therapeutic option for asthma and COPD? Drugs 2007; 67:503-515
14. 2- adrenoceptor agonist, on small airways in human and rat precision-cut lung slices. J Pharmacol Exp Ther 2008; 324:270-275
15. Rennard S, Bantje T, Centanni S, et al. A dose-ranging study of indacaterol in obstructive airways disease, with a tiotropium comparison. Respir Med 2008; 102:1033-1044
16. Hansel TT, Neighbour H, Erin EM, et al. Glycopyrrolate causes prolonged bronchoprotection and bronchodilatation in patients with asthma. Chest 2005; 128:1974-1979
17. Joos GF, Schelfhout VJ, Kanniess F, et al. Bronchodilator effects of aclidinium bromide, a novel long-acting anticholinergic, in COPD patients: a phase II study [abstract]. Eur Respir J 2007; 30(suppl):1299
18. van Noord JA, Aumann JL, Janssens E, et al. Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD. Chest 2006; 129:509-517
19. Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev (database online). Issue 1, 2007
20. Cahill K, Ussher M. Cannabinoid type 1 receptor antagonists (rimonabant) for smoking cessation. Cochrane Database Syst Rev (database online). Issue 3, 2007
21. Siu EC, Tyndale RF. Non-nicotinic therapies for smoking cessation. Annu Rev Pharmacol Toxicol 2007; 47:541-564
22. Barnes PJ. Mediators of chronic obstructive pulmonary disease. Pharm Rev 2004; 56:515-548
23. Barnes PJ. Cytokine networks in asthma and chronic obstructive pulmonary disease. J Clin Invest 2008; 118:3546-3556
24. Hicks A, Monkarsh SP, Hoffman AF, et al. Leukotriene B4 receptor antagonists as therapeutics for inflammatory disease: preclinical and clinical developments. Expert Opin Investig Drugs 2007; 16:1909-1920
25. Rennard SI, Fogarty C, Kelsen S, et al. The safety and efficacy of infliximab in moderate-to-severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 175:926-934
26. Erin EM, Leaker BR, Nicholson GC, et al. The effects of a monoclonal antibody directed against tumor necrosis factor-α in asthma. Am J Respir Crit Care Med 2006; 174:753-762
27. Barnes PJ. Unexpected failure of anti-tumor necrosis factor therapy in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 175:866-867
28. Paul-Pletzer K. Tocilizumab: blockade of interleukin-6 signaling pathway as a therapeutic strategy for inflammatory disorders. Drugs Today (Barc) 2006; 42:559-576
29. Donnelly LE, Barnes PJ. Chemokine receptors as therapeutic targets in chronic obstructive pulmonary disease. Trends Pharmacol Sci 2006; 27:546-553
30. Mahler DA, Huang S, Tabrizi M, et al. Efficacy and safety of a monoclonal antibody recognizing interleukin-8 in COPD: a pilot study. Chest 2004; 126:926-934
31. O'Connor BJ, Leaker BR, Barnes PJ, et al. Inhibition of LPS-induced neutrophilic inflammation in healthy volunteers [abstract]. Eur Respir J 2007; 30(suppl):1294
32. Costa C, Rufino R, Traves SL, et al. CXCR3 and CCR5 chemokines in the induced sputum from patients with COPD. Chest 2008; 133:26-33
33. Koli K, Myllarniemi M, Keski-Oja J, et al. Transforming growth factor-β activation in the lung: focus on fibrosis and reactive oxygen species. Antioxid Redox Signal 2008; 10:333-342
34. Wang IM, Stepaniants S, Boie Y, et al. Gene expression profiling in patients with chronic obstructive pulmonary disease and lung cancer. Am J Respir Crit Care Med 2008; 177:402-411
35. Leung SY, Niimi A, Noble A, et al. Effect of transforming growth factor-β receptor I kinase inhibitor 2,4-disubstituted pteridine (SD-208) in chronic allergic airway inflammation and remodeling. J Pharmacol Exp Ther 2006; 319:586-594
36. Hu J, Van Den Steen PE, Sang QX, et al. Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases. Nat Rev Drug Discov 2007; 6:480-498
37. Churg A, Wang R, Wang X, et al. Effect of an MMP-9/ MMP-12 inhibitor on smoke-induced emphysema and airway remodelling in guinea pigs. Thorax 2007; 62:706-713
38. Chung KF. Phosphodiesterase inhibitors in airways disease. Eur J Pharmacol 2006; 533:110-117
39. Martorana PA, Beume R, Lucattelli M, et al. Roflumilast fully prevents emphysema in mice chronically exposed to cigarette smoke. Am J Respir Crit Care Med 2005; 172:848-853
40. Grootendorst DC, Gauw SA, Verhoosel RM, et al. Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD. Thorax 2007; 62:1081-1087
41. Rabe KF, Bateman ED, O'Donnell D, et al. Roflumilast: an oral anti-inflammatory treatment for chronic obstructive pulmonary disease; a randomised controlled trial. Lancet 2005; 366:563-571
42. Calverley PM, Sanchez-Toril F, McIvor A, et al. Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 176:154-161
43. Peter D, Jin SL, Conti M, et al. Differential expression and function of phosphodiesterase 4 (PDE4) subtypes in human primary CD4+ T cells: predominant role of PDE4D. J Immunol 2007; 178:4820-4831
44. Smith SJ, Cieslinski LB, Newton R, et al. Discovery of BRL 50481, a selective inhibitor of phosphodiesterase 7: in vitro studies in human monocytes, lung macrophages and CD8+ T-lymphocytes. Mol Pharmacol 2004; 66:1679-1689
45. Giembycz MA. Phosphodiesterase-4: selective and dual-specificity inhibitors for the therapy of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2005; 2:326-333
46. Birrell MA, Wong S, Hardaker EL, et al. IκB kinase-2-independent and -dependent inflammation in airway disease models: relevance of IKK-2 inhibition to the clinic. Mol Pharmacol 2006; 69:1791-1800
47. Tudhope SJ, Catley MC, Fenwick PS, et al. The role of IκB kinase 2, but not activation of NF-κB, in the release of CXCR3 ligands from IFN-γ-stimulated human bronchial epithelial cells. J Immunol 2007; 179:6237-6245
48. Renda T, Baraldo S, Pelaia G, et al. Increased activation of p38 MAPK in COPD. Eur Respir J 2008; 31:62-69
49. Smith SJ, Fenwick PS, Nicholson AG, et al. Inhibitory effect of p38 mitogen-activated protein kinase inhibitors on cytokine release from human macrophages. Br J Pharmacol 2006; 149:393-404
50. Medicherla S, Fitzgerald M, Spicer D, et al. p38a selective MAP kinase inhibitor, SD-282, reduces inflammation in a sub-chronic model of tobacco smoke-induced airway inflammation. J Pharmacol Exp Ther 2007; 324:921-929
51. Tudhope SJ, Finney-Hayward TK, Nicholson AG, et al. Different mitogen-activated protein kinase-dependent cytokine responses in cells of the monocyte lineage. J Pharmacol Exp Ther 2008; 324:306-312
52. Medina-Tato DA, Ward SG, Watson ML. Phosphoinositide 3-kinase signalling in lung disease: leucocytes and beyond. Immunology 2007; 121:448-461
53. Ward S, Sotsios Y, Dowden J, et al. Therapeutic potential of phosphoinositide 3-kinase inhibitors. Chem Biol 2003; 10:207-213
54. Belvisi MG, Hele DJ, Birrell MA. Peroxisome proliferator-activated receptor γ agonists as therapy for chronic airway inflammation. Eur J Pharmacol 2006; 533:101-109
55. Remels AH, Schrauwen P, Broekhuizen R, et al. Peroxisome proliferator-activated receptor expression is reduced in skeletal muscle in COPD. Eur Respir J 2007; 30:245-252
56. Yang IA, Fong KM, Sim EH, et al. Inhaled corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev (database online). Issue 2, 2007
57. Suissa S, Ernst P, Vandemheen KL, et al. Methodological issues in therapeutic trials of COPD. Eur Respir J 2008; 31:927-933
58. Barnes PJ. Reduced histone deacetylase in COPD: clinical implications. Chest 2006; 129:151-155
59. Ito K, Yamamura S, Essilfie-Quaye S, et al. Histone deacetylase 2-mediated deacetylation of the glucocorticoid receptor enables NF-κB suppression. J Exp Med 2006; 203:7-13
60. Cosio BG, Tsaprouni L, Ito K, et al. Theophylline restores histone deacetylase activity and steroid responses in COPD macrophages. J Exp Med 2004; 200:689-695
61. Fox JC, Spicer D, Ito K, et al. Oral or inhaled corticosteroid combination therapy with low dose theophylline reverses corticosteroid insensitivity in a smoking mouse model [abstract]. Proc Am Thorac Soc 2007; 2:A637
62. Kirkham P, Rahman I. Oxidative stress in asthma and COPD: antioxidants as a therapeutic strategy. Pharmacol Ther 2006; 111:476-494
63. Charron C, Sumakuza T, Oomura S, et al. EM-703, a non-antibacterial erythromycin derivative, restores HDAC2 activation diminished by hypoxia and oxidative stress [abstract]. Proc Am Thorac Soc 2007; 175:A640
64. Stinchcombe SV, Maden M. Retinoic acid-induced alveolar regeneration: critical differences in strain sensitivity. Am J Respir Cell Mol Biol 2008; 38:185-191
65. Roth MD, Connett JE, D'Armiento JM, et al. Feasibility of retinoids for the treatment of emphysema study. Chest 2006; 130:1334-1345
66. Wang D, Haviland DL, Burns AR, et al. A pure population of lung alveolar epithelial type II cells derived from human embryonic stem cells. Proc Natl Acad Sci U S A 2007; 104:4449-4454
67. Loebinger MR, Janes SM. Stem cells for lung disease. Chest 2007; 132:279-285
68. Stolk J, Versteegh MI, Montenij LJ, et al. Densitometry for assessment of effect of lung volume reduction surgery for emphysema. Eur Respir J 2007; 29:1138-1143